New depression drug NH102 passes early safety check in healthy volunteers
NCT ID NCT07324408
First seen Jan 11, 2026 · Last updated Apr 29, 2026 · Updated 16 times
Summary
This early-stage study tested the safety of a new drug called NH102, which is being developed for depression. Forty healthy adults received either the drug or a placebo to check for side effects and how the drug moves through the body. The goal was not to treat depression but to make sure the drug is safe before testing it in people with depression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEPRESSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Mental Health Center
Shanghai, Shanghai Municipality, 201108, China
Conditions
Explore the condition pages connected to this study.